Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Evolocumab in Pediatric HeFH
NCT02392559Phase 3Completed
- Sponsor
- Amgen
- Start
- Mar 2016
- Primary completion
- Nov 2019
- Modality
- Monoclonal Antibodies
- Countries
- 26
01
Overview
Phase 3, randomised, double-blind trial of evolocumab in heterozygous familial hypercholesterolemia (HeFH) (2 arms), sponsored by Amgen. Primary endpoint: Percent Change From Baseline to Week 24 in LDL-C. Started Mar 2016; status: completed.
02
Drugs
evolocumab
03
Conditions
heterozygous familial hypercholesterolemia (HeFH)
Beyond the preview
Go deeper on NCT02392559.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02392559.